← Eichor
Study identifier: NCT05018663 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Artificial Intelligence (AI) Cytopathology Trial

Condition: Pancreatic Solid Lesions  ·  Sponsor: The University of Texas Health Science Center, Houston

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.

This description comes directly from the study's public registry record.

Talk to the study team

Prithvi B Patil, MS  ·  7135006456  ·  prithvi.b.patil@uth.tmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Memorial Hermann HospitalHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05018663